Community Health Systems to Sell Four Arkansas Hospitals for $112 Million
CYH sits 55% above its 52-week low of $2.241.
Summary
Community Health Systems' subsidiary signed a definitive agreement to sell four Arkansas hospitals and related businesses for $112 million, as part of its strategic divestiture plan.
Key Events · M&A and Partnerships · CYH
-
Definitive Asset Purchase Agreement Signed
CHS/Community Health Systems, Inc., a wholly-owned subsidiary, entered into an Asset Purchase Agreement with Freeman-Oak Hill Health System.
-
Four Arkansas Hospitals Divested
The agreement covers the sale of substantially all assets and certain liabilities related to Northwest Medical Center - Bentonville, Northwest Medical Center - Springdale, Northwest Medical Center - Willow Creek Women's Hospital, and Siloam Springs Regional Hospital, along with associated outpatient centers and practices.
-
Purchase Price of $112 Million
The total purchase price for the divested assets is $112 million, subject to certain adjustments based on closing net working capital and assumed finance leases.
-
Expected Closing in Q2 2026
The transaction is anticipated to close in the second quarter of 2026, pending customary regulatory approvals and closing conditions.
Analysis · CYH · Industrial Applications And Services
Community Health Systems has entered into a definitive agreement to sell four Arkansas hospitals and related assets for $112 million. This transaction represents a substantial divestiture, aligning with the company's previously announced strategic plan to optimize its portfolio. The significant cash proceeds from this sale are expected to strengthen the company's balance sheet and provide financial flexibility, following its recent financial turnaround. Investors should monitor the successful closing of the transaction and the company's allocation of the proceeds.
At the time of this filing, CYH was trading at $3.48 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $472.7M. The 52-week trading range was $2.24 to $4.47. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.